Cytokinetics (CYTK) Stock Price, News & Analysis

Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $43.52 to $45.00
• 50-Day Range: $41.56 to $51.12
• 52-Week Range: $40.53 to $75.71
• Volume: 584,503 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $5.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $82.00
• Consensus Rating: Moderate Buy

Cytokinetics Stock Analysis - MarketRank™

Cytokinetics scored higher than 86% of companies evaluated by MarketBeat, and ranked 131st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cytokinetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytokinetics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytokinetics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.19% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Cytokinetics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytokinetics does not currently pay a dividend.

Dividend Growth

Cytokinetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

12.19% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Cytokinetics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.53

News Sentiment

Cytokinetics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Cytokinetics this week, compared to 9 articles on an average week.

Search Interest

Only 9 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,296,370.00 in company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Cytokinetics is held by insiders.

CYTK Stock Analysis - Frequently Asked Questions

How have CYTK shares performed this year?

Cytokinetics' stock was trading at $47.04 at the start of the year. Since then, CYTK stock has decreased by 5.3% and is now trading at $44.55.
View the best growth stocks for 2025 here.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.03. The biopharmaceutical company earned $16.93 million during the quarter, compared to analysts' expectations of $14.26 million.

Who are Cytokinetics' major shareholders?

Cytokinetics' top institutional shareholders include Vanguard Group Inc. (10.10%), T. Rowe Price Investment Management Inc. (9.11%), Geode Capital Management LLC (2.41%) and Price T Rowe Associates Inc. MD (2.22%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, Andrew Callos, John T Henderson, Wendall Wierenga, B Lynne Parshall, Muna Bhanji, Robert Wong, Robert Arthur Harrington and Mark A Schlossberg.
View institutional ownership trends.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and General Electric (GE).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTK
• CIK: 1061983
• Web: www.cytokinetics.com
• Phone: (650) 624-3000
• Fax: 650-624-3010
• Employees: 250
• Year Founded: 1997

Price Target and Rating

• Average Stock Price Target: $82.00
• High Stock Price Target: $120.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +82.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-526,240,000.00
• Net Margins: -17,906.25%
• Pretax Margin: -17,906.25%
• Return on Equity: N/A
• Return on Assets: -50.21%

Debt

• Debt-to-Equity Ratio: 5.93
• Current Ratio: 9.28
• Quick Ratio: 9.28

Sales & Book Value

• Annual Sales: $18.47 million
• Price / Sales: 287.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.94) per share
• Price / Book: -11.40

Miscellaneous

• Outstanding Shares: 118,411,000
• Free Float: 114,002,000
• Market Cap: $5.32 billion
• Optionable: Optionable
• Beta: 0.95